Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
UPPSALA, Sweden , July 10, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed an agreement granting Mundipharma Pty Limited (Mundipharma Australia) the exclusive rights t...
UPPSALA, Sweden , July 9, 2019 /PRNewswire/ --Orexo AB (publ.) has resolved to prepay SEK 32.5 million , corresponding to 10 percent, of the unsecured corporate bond loan of in total SEK 325 million , which was issued by the company in November 2017 and which carries a floatin...
NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series. Individual investors, institutional investors, advisors and analysts are invited to ...
UPPSALA, Sweden , June 12, 2019 /PRNewswire/ -- Orexo AB (publ.) announces that the company has resolved to issue and immediately thereafter repurchase 63,000 class C shares. The shares are issued and repurchased in accordance with the long-term incentive programme, LTIP 2019, which ...
UPPSALA, Sweden , May 17, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will be presenting at the following events taking place in May and June. [1] timing of...
Orexo AB (publ) ( OTCQX:ORXOY ): Q1 GAAP EPS of SEK0.40. More news on: Orexo AB (publ), OREXO AB ORD, Earnings news and commentary, Healthcare stocks news, Read more ...
UPPSALA, Sweden , May 2, 2019 /PRNewswire/ -- Q1 2019 highlights Total net revenues of SEK 174.3 million (139.7), up 24.8 percent Zubsolv® US net revenues of SEK 161.7 million (131.1), up 23.3 percent in SEK and 9.3 percent in local currency EBITDA of SEK 12.0 mill...
UPPSALA, Sweden , April 26, 2019 /PRNewswire/ -- The 2016 annual general meeting of Orexo resolved on a long-term incentive plan for senior executives and key employees within the Orexo group ("LTIP 2016/2019"). Participants in LTIP 2016/2019 were granted share awards, entitling to shares...
UPPSALA, Sweden , March 29, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company, with strong long-term patent protection (no. 8,940,330) for its key product, Zubsolv® in the US , until September 2032 , announces that the US District Court fo...
UPPSALA, Sweden , March 21, 2019 /PRNewswire/ -- Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's website, www.orexo.com (investors/reports, presentations and audiocasts). A PDF version is also...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...